Trial Profile
A Phase 2 Proof-of-Concept Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Non-small Cell Lung Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Acalabrutinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms KEYNOTE166
- Sponsors Acerta Pharma
- 07 Jun 2019 Status changed from active, no longer recruiting to completed.
- 06 May 2016 Status changed from recruiting to active, no longer recruiting.
- 20 May 2015 New trial record